The new concept of therapeutic strategy for neuroendocrine tumors: important information from a case report of gastrinoma.
Igarashi
Hisato
H
Ito
Tetsuhide
T
Takayanagi
Ryoichi
R
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004379:Duodenal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D015408:Gastrinoma / Q000737:chemistry / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D018761:Multiple Endocrine Neoplasia Type 1; D009363:Neoplasm Proteins / Q000032:analysis / Q000187:drug effects; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D017481:Receptors, Somatostatin / Q000032:analysis / Q000187:drug effects; D012074:Remission Induction; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy / Q000235:genetics
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D009363:Neoplasm Proteins; D017481:Receptors, Somatostatin; C093733:somatostatin receptor 2; D015282:Octreotide